It also implies that the effectiveness of PDE4 inhibitors for neurodegeneration may not be the only consequence of modulating neuroinflammation as in the case of many previous clinical studies, but also regulating mitochondrial biology (which is the primary mechanism involved in CHCHD10S59L associated ALS-FTD). Here, PDE4A is linked to frontotemporal dementia.